What happened in optometry this week: October 28 - November 1

Blog
Article

Catch up on what happened in optometry during the week of October 28-November 1.

Catch up with what Optometry Times shared this week:

CORXEL and LENZ Therapeutics announce positive topline data from China phase 3 presbyopia trial of LNZ100

By Lynda Charters

Corxel Pharmaceuticals (CORXEL) and LENZ Therapeutics released positive topline data from the phase 3 JX07001 clinical trial of LNZ100 (1.75% aceclidine HCl, a miotic) in presbyopic Chinese patients.

The phase 3 safety and efficacy results showed that the drug met the primary endpoint and key secondary endpoints, with 3 lines or more improvements in the best-corrected distance visual acuity (VA) at near and the patients maintained their optimal distance VA, defined as no loss of 5 or more letters, according to a press release.

Read more...

Contact Lens Institute releases full report on contact lens wearer retention

By Jordana Joy, Associate Editor

Following consumer data released in late September,1 the Contact Len Institute (CLI) has released the full report that detailed new and long-term soft contact users’ rates of retention. The report, entitled “Disrupting the Dropout Dilemma: Practical Steps to Keep Patients in Contact Lenses,” found that satisfaction in contact lens wear was generally high across all survey participants.2

Read here...

A model to predict iris melanoma

By Lynda Charters

Arun Singh, MD, and colleagues developed a model that provides direct diagnostic prediction of a lesion being iris melanoma.1 He is Director of the Department of Ophthalmic Oncology, Cole Eye Institute at the Cleveland Clinic, Cleveland Clinic Main Campus Hospital, Cleveland.

The investigators conducted a retrospective consecutive case series that included 100 cases of pathologically confirmed iris melanoma and 112 cases of iris naevus, with either pathological confirmation or documented stability exceeding 1 year.

Read here...

AAOpt 2024: AAO-sponsored report recommends a disease classification for myopia

By Jordana Joy, Associate Editor

The American Academy of Optometry has sponsored a National Academies of Sciences, Engineering, and Medicine (NASEM) that has recommended that the Centers for Medicare and Medicaid Services classify myopia as a disease.1 The report, entitled “Myopia: Causes, Prevention, and Treatment of an Increasingly Common Disease,” compiled from a consensus study, works to identify and assess the current mechanistic understanding of myopia pathogenesis and the causes of its increased prevalence.

Read here...

Cutting back on screen time for the sake of myopia management

By Erin Tomiyama, OD, PhD, FAAO

In an increasingly digital world, the rise of myopia has become a significant concern. Although it is easy to assume there is a direct connection between screen time and the myopia epidemic, the prevalence of myopia has been on the rise long before the increased use of screen time in children. In the early 2000s, the prevalence of myopia was almost double that in the 1970s.1 Despite this observation, myopia development is multifactorial, thus the relationship between screen time and myopia must be explored.

Read here...

Recent Videos
Danielle Crull, ABOM, and Truffles of A Child's Eyes talk pediatric eye health and initiatives
Danielle Crull and Truffles the Kitty talk eye care initiatives for pediatric patients
World Sight Day 2024
Danielle Crull, ABOM, and Truffles of A Child's Eyes talk pediatric eye health and initiatives
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Pediatric optometrist Dr. Magdela Stec speaks about myopia management at EyeCon 2024
Dr. Mark Dunbar chats about his EyeCon 2024 presentation about diabetic eye care
Dr. Khanh Hoang at EyeCon 2024 receiving the Visionary in Eye Care Award
Dr Adam Wenick at EyeCon 2024
David Chin Yee, MD, at EyeCon 2024
© 2024 MJH Life Sciences

All rights reserved.